| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2025―Jun―24 |
Thiazole-fused thiazoliniums with ketone warheads as covalent inhibitors targeting Cys44 of SARS-CoV-2 3CLpro |
Qizhen Cao, Zhaoqin Zhang, Guanghao Zhu, Sanfeng Dong, Xue Sun, Yuqing Song, et al. (+9) Ya Zhang, Tingting Cai, Xinben Zhang, Yong Zhang, Zhijian Xu, Ruisheng Xiong, Weiliang Zhu, Guangbo Ge, Bo Li |
| 2 |
[GO] |
2023―Mai―19 |
Serum butyrylcholinesterase as a marker of COVID-19 mortality: Results of the monocentric prospective observational study |
Lucia Markuskova, Zuzana Javorova Rihova, Tomas Fazekas, Anna Martinkovicova, Martina Havrisko, Dominika Dingova, et al. (+3) Maria Solavova, Daria Rabarova, Anna Hrabovska |
| 3 |
[GO] |
2023―Feb―22 |
Investigating the competition between ACE2 natural molecular interactors and SARS-CoV-2 candidate inhibitors |
Edoardo Milanetti, Mattia Miotto, Leonardo Bo’, Lorenzo Di Rienzo, Giancarlo Ruocco |
| 4 |
[GO] |
2023―Jan―13 |
Discovery of inhibitors against SARS-CoV-2 main protease using fragment-based drug design |
Hai Ping Shao, Tian Hua Wang, Hong Lin Zhai, Ke Xin Bi, Bing Qiang Zhao |
| 5 |
[GO] |
2023―Jan―11 |
Multi-target activity of copper complexes; antibacterial, DNA binding, and molecular docking with SARS-CoV-2 receptor |
P. Arthi, M. Dharmasivam, B. Kaya, Kalilur Rahiman A |
| 6 |
[GO] |
2022―Nov―03 |
Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation |
J.A. Rodriguez, J. Gonzalez, C.E. Arboleda-Bustos, N. Mendoza, C. Martinez, A. Pinzon |
| 7 |
[GO] |
2022―Sep―15 |
Antiviral potential of diminazene aceturate against SARS-CoV-2 proteases using computational and in vitro approaches |
Esley S. Santos, Priscila C. Silva, Paulo S.A. Sousa, Cristhyane C. Aquino, Gabriella Pacheco, Luiz F.L.S. Teixeira, et al. (+7) Alyne R. Araujo, Francisca B.M. Sousa, Romulo O. Barros, Ricardo M. Ramos, Jefferson A. Rocha, Lucas A.D. Nicolau, Jand V.R. Medeiros |
| 8 |
[GO] |
2022―Sep―13 |
Integrating in silico and in vivo approach for investigating the role of polyherbal oil in prevention and treatment of COVID-19 infection |
Amul S. Bahl, Vipin Kumar Verma, Jagriti Bhatia, Dharamvir Singh Arya |
| 9 |
[GO] |
2022―Aug―11 |
In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir |
Qingchen Zhang, Philip W. Melchert, John S. Markowitz |
| 10 |
[GO] |
2022―Mai―31 |
Pharmacology of COVID-19 |
Antoni Sureda, Solomon Habtemariam, Seyed M. Nabavi |
| 11 |
[GO] |
2022―Mai―20 |
TRPC6 is altered in COVID-19 pneumonia |
Gina Leidinger, Fidelis Flockerzi, Johannes Hohneck, Rainer M. Bohle, Armin Fieguth, Thomas Tschernig |
| 12 |
[GO] |
2022―Apr―22 |
Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19 |
Xiuge Gao, Xian Jing, Junqi Wang, Yuling Zheng, Yawei Qiu, Hui Ji, et al. (+4) Lin Peng, Shanxiang Jiang, Wenda Wu, Dawei Guo |
| 13 |
[GO] |
2022―Mrz―21 |
Gut Microbiota Disruption in COVID-19 or Post-COVID Illness Association with severity biomarkers: A Possible Role of Pre / Pro-biotics in manipulating microflora |
Khalid Saad Alharbi, Yogendra Singh, Waleed Hassan almalki, Sushama Rawat, Obaid Afzal, Abdulmalik Saleh Alfawaz Altamimi, et al. (+8) Imran Kazmi, Fahad A. Al-Abbasi, Sami I. Alzarea, Sachin Kumar Singh, Shvetank Bhatt, Dinesh Kumar Chellappan, Kamal Dua, Gaurav Gupta |
| 14 |
[GO] |
2022―Jan―26 |
The influence of renin angiotensin aldosterone system (RAAS), endothelial nitric oxide synthase (eNOS) and erythropoietin (EPO) on COVID-19 complications |
Konstantinos I. Papadopoulos, Warachaya Sutheesophon, Tar-Choon Aw |
| 15 |
[GO] |
2022―Jan―07 |
Cathepsin B is a potential therapeutic target for coronavirus disease 2019 patients with lung adenocarcinoma |
Xiaoyan Ding, Nan Ye, Minyue Qiu, Hongxia Guo, Junjie Li, Xiaoyang Zhou, et al. (+5) Maocheng Yang, Jing Xi, Yongjie Liang, Yuanxin Gong, Jintao Li |
| 16 |
[GO] |
2021―Dez―09 |
Comparisons of the immunological landscape of COVID-19 patients based on sex and disease severity by multi-omics analysis |
Tianfang Zhang, Zeinab Abdelrahman, Qian Liu, Xiaosheng Wang, Zuobing Chen |
| 17 |
[GO] |
2021―Nov―03 |
Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin-angiotensin-aldosterone system (RAAS) dysregulation |
Robin Augustine, Abhilash S, Ajisha Nayeem, Shaheen Abdul Salam, Priya Augustine, Pan Dan, et al. (+6) Pablo Monteiro, Fatima Mraiche, Carmine Gentile, Philip M. Hansbro, Lana McClements, Anwarul Hasan |
| 18 |
[GO] |
2021―Sep―11 |
Von Willebrand factor: A key glycoprotein involved in thrombo-inflammatory complications of COVID-19 |
Shalki Choudhary, Kajal Sharma, Pankaj Kumar Singh |
| 19 |
[GO] |
2021―Jul―23 |
Differential mutation profile of SARS-CoV-2 proteins across deceased and asymptomatic patients |
Rezwanuzzaman Laskar, Safdar Ali |
| 20 |
[GO] |
2021―Jul―17 |
Computational analysis of TMPRSS2 expression in normal and SARS-CoV-2-infected human tissues |
Wenxiu Cao, Qiushi Feng, Xiaosheng Wang |
| 21 |
[GO] |
2021―Jun―22 |
TRP channels in COVID-19 disease: Potential targets for prevention and treatment |
Sahar M. Jaffal, Manal A. Abbas |
| 22 |
[GO] |
2021―Mai―13 |
A novel nano therapeutic using convalescent plasma derived exosomal (CPExo) for COVID-19: A combined hyperactive immune modulation and diagnostics |
Krishnan Anand, Chithravel Vadivalagan, Jitcy Saji Joseph, Sachin Kumar Singh, Monica Gulati, Mohd Shahbaaz, et al. (+5) Magda H. Abdellattif, Parteek Prasher, Gaurav Gupta, Dinesh Kumar Chellappan, Kamal Dua |
| 23 |
[GO] |
2021―Mai―08 |
Elucidating of oxidative distress in COVID-19 and methods of its prevention |
Anna-Maria Barciszewska |
| 24 |
[GO] |
2021―Apr―20 |
Potent Toxic Effects of Taroxaz-104 on the Replication of SARS-CoV-2 Particles |
Amgad M. Rabie |
| 25 |
[GO] |
2021―Mrz―30 |
Role of phytoconstituents in the management of COVID-19 |
Amiya Das, Deepti Pandita, Gaurav Kumar Jain, Pallavi Agarwal, Ajmer Singh Grewal, Roop K. Khar, Viney Lather |
| 26 |
[GO] |
2021―Feb―18 |
Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis |
Yajing Hou, Shuai Ge, Xiaowei Li, Cheng Wang, Huaizhen He, Langchong He |
| 27 |
[GO] |
2021―Jan―08 |
Expression of SARS-COV-2 cell receptor gene ACE2 is associated with immunosuppression and metabolic reprogramming in lung adenocarcinoma based on bioinformatics analyses of gene expression profiles |
Md. Nazim Uddin, Rehana Akter, Mengyuan Li, Zeinab Abdelrahman |
| 28 |
[GO] |
2020―Dez―11 |
Thermovaccination - thermoheliox as a stimulator of the immune response. Kinetics of the synthesis of antibodies and C-reactive protein in coronavirus infection |
Sergey D. Varfolomeev, Alexander A. Panin, Valeriy I. Bykov, Svetlana B. Tsybenova, Sergey V. Zhuravel, Anna M. Ryabokon, et al. (+5) Irina I. Utkina, Pavel V. Gavrilov, Sergey S. Petrikov, Lyudmila V. Shogenova, Alexander G. Chuchalin |
| 29 |
[GO] |
2020―Dez―02 |
2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease |
Katrina L. Forrestall, Darcy E. Burley, Meghan K. Cash, Ian R. Pottie, Sultan Darvesh |
| 30 |
[GO] |
2020―Nov―09 |
In silico analysis of selected alkaloids against main protease (Mpro) of SARS-CoV-2 |
Saksham Garg, Arpita Roy |
| 31 |
[GO] |
2020―Okt―27 |
Race to arsenal COVID-19 therapeutics: Current alarming status and future directions |
Ankit Kumar Dubey, Aakansha Singh, Shardendu Prakash, Manoj Kumar, Ashok K. Singh |
| 32 |
[GO] |
2020―Okt―06 |
Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19 |
Amjad Husain, Siddappa N. Byrareddy |
| 33 |
[GO] |
2020―Jul―28 |
Roles of flavonoids against coronavirus infection |
Maria Russo, Stefania Moccia, Carmela Spagnuolo, Idolo Tedesco, Gian Luigi Russo |
